NYSE:MYOV • BMG637AM1024
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Myovant Sciences Ltd (MYOV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-10-26 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2022-10-25 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-10-24 | Baird | Downgrade | Outperform -> Neutral |
| 2022-08-09 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2022-07-28 | Goldman Sachs | Maintains | Neutral |
| 2022-05-11 | Goldman Sachs | Maintains | Neutral |
| 2022-04-13 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-05 | SVB Leerink | Maintains | Market Perform |
| 2021-10-27 | SVB Leerink | Maintains | Market Perform |
| 2021-09-09 | SVB Leerink | Initiate | Market Perform |
| 2021-02-12 | SVB Leerink | Maintains | Market Perform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 59.32M | 230.972M 289.37% | 427.93M 85.27% | 556.07M 29.94% | 701.44M 26.14% | 1.082B 54.25% | 1.524B 40.85% | 1.593B 4.53% | 1.704B 6.97% | ||
| EBITDA YoY % growth | -273.09M -3.27% | -258.28M 5.42% | -185.968M 28.00% | -100.104M 46.17% | -106.65M -6.54% | -81.471M 23.61% | 256.57M 414.92% | N/A | N/A | N/A | |
| EBIT YoY % growth | -274.89M -3.80% | -260.78M 5.13% | -187.346M 28.16% | -100.907M 46.14% | -43.936M 56.46% | 47.512M 208.14% | -2.142M -104.51% | 334.66M 15,723.72% | 247.96M -25.91% | 417.18M 68.24% | |
| Operating Margin | N/A | -439.62% | -81.11% | -23.58% | -7.90% | 6.77% | -0.20% | 21.96% | 15.57% | 24.48% | |
| EPS YoY % growth | -3.32 18.63% | -2.83 14.76% | -2.21 21.91% | -1.78 19.42% | -0.93 47.54% | -0.54 42.50% | 0.96 278.46% | 2.35 144.71% | 1.73 -26.09% | N/A |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.52 17.83% | -0.28 -26.73% | -0.36 22.96% | 0.07 111.24% | -0.20 60.59% |
| Revenue Q2Q % growth | 107.87M 87.38% | 126.26M 8.39% | 130.45M 24.45% | 185.3M 84.88% | 169.68M 57.30% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -32.985M 36.49% | -21.035M -124.71% | -35.589M -5.57% | 9.264M 117.85% | -19.132M 42.00% |
All data in USD
10 analysts have analysed MYOV and the average price target is 27.54 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 26.98.
Myovant Sciences Ltd (MYOV) will report earnings on 2023-05-08, after the market close.
The consensus EPS estimate for the next earnings of Myovant Sciences Ltd (MYOV) is -0.52 USD and the consensus revenue estimate is 107.87M USD.
The expected long term growth rate for Myovant Sciences Ltd (MYOV) is 43.72%.